Lantern Pharma Inc
$ 3.74
0.00%
02 Jun - close price
- Market Cap 47,718,200 USD
- Current Price $ 3.74
- High / Low $ 3.98 / 3.52
- Stock P/E N/A
- Book Value 0.58
- EPS -1.45
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.73 %
- ROE -1.57 %
- 52 Week High 5.74
- 52 Week Low 1.11
About
Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.
Analyst Target Price
$20.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-03-30 | 2025-11-12 | 2025-08-13 | 2025-05-15 | 2025-03-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-18 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.3 | -0.36 | -0.39 | -0.4 | -0.42 | -0.54 | -0.42 | -0.46 | -0.51 | -0.39 | -0.29 | -0.44 |
| Estimated EPS | -0.36 | -0.46 | -0.44 | -0.53 | -0.43 | -0.51 | -0.56 | -0.55 | -0.43 | -0.4 | -0.45 | -0.43 |
| Surprise | 0.06 | 0.1 | 0.05 | 0.13 | 0.01 | -0.03 | 0.14 | 0.09 | -0.08 | 0.01 | 0.16 | -0.01 |
| Surprise Percentage | 16.6667% | 21.7391% | 11.3636% | 24.5283% | 2.3256% | -5.8824% | 25% | 16.3636% | -18.6047% | 2.5% | 35.5556% | -2.3256% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LTRN
2026-06-02 12:10:29
Lantern Pharma announced new data from its HARMONIC™ trial, indicating that LP-300, in combination with chemotherapy, shows a deepening progression-free survival (PFS) benefit with longer treatment duration in EGFR Exon 21 L858R lung cancer patients. Patients treated for up to six cycles achieved an 8.9-month median PFS, with durable responses and a favorable safety profile compared to existing treatments. The company is using this data for partnering discussions during ASCO 2026 and plans to extend LP-300 dosing to eight cycles, focusing on the L858R subgroup.
2026-06-02 00:10:29
Lantern Pharma Inc. (LTRN) filed an 8-K to furnish an investor-style presentation about its Harmonic™ Phase 2 clinical trial for the LP-300 product candidate. The presentation, used on June 1, 2026, is attached as Exhibit 99.1 and is designated as "furnished" rather than "filed," meaning it's not subject to certain liability provisions of the Exchange Act unless specifically referenced. This disclosure provides stakeholders with information on the clinical trial's status and discussion materials.
2026-05-29 13:38:49
This article provides recent news and financial updates for Lantern Pharma Inc. (NASDAQ: LTRN). Key announcements include successful FDA Type C meeting results for its HARMONIC™ Phase 2 trial of LP-300, the report of Q1 2026 financial results, and two recent direct offerings totaling up to $9.25 million. The stock price closed at $3.59 USD, up 2.57%.
2026-05-27 00:10:46
This article provides a technical analysis of LANTERN PHARMA INC (NASDAQ:LTRN), assigning it an overall technical rating of 8 out of 10. Both medium and short-term trends are positive, with the stock currently trading near the high end of its monthly range. However, the analysis also notes potential overbought conditions indicated by high RSI and Stochastics values, recommending waiting for a consolidation before entry.
2026-05-19 14:38:56
Lantern Pharma announced that the FDA raised no objections to their proposed amendments for the HARMONIC™ Phase 2 trial of LP-300. The amendments include focusing enrollment on never-smokers with EGFR exon 21 L858R mutations, extending LP-300 dosing to eight cycles, and transitioning to a single-arm study design. These changes aim to streamline the regulatory path and enhance the potential for LP-300 in a high-need patient population given its differentiated safety profile and emerging efficacy signals.
2026-05-19 11:09:43
Lantern Pharma received a successful response from the FDA regarding its Type C meeting request for the HARMONIC™ Phase 2 trial of LP-300 in never-smokers with advanced NSCLC. The FDA had no objections to protocol amendments, which include enriching enrollment for patients with EGFR exon 21 L858R mutations, extending LP-300 dosing to eight cycles, and transitioning to a single-arm study design. These changes aim to refine the trial's focus on a high-need patient population and accelerate enrollment, supported by emerging data showing potential benefit and a favorable safety profile for LP-300.
